Biomarker Solutions

Today it is inconceivable that any new drug would be developed without simultaneously looking at a multitude of biomarkers.

This is because Biomarkers are indispensable as:

• Efficacy markers – to validate a new drug candidate’s effectiveness or prove competitive advantage, preventing huge costs from pursuing ineffective drug candidates
• Toxicity markers – From pre-clinical through to Phase III, it’s vital to determine toxicity as early as possible as late failures carry enormous costs
• Tools to speed up clinical trials – biomarkers provide objective feedback (surrogate endpoints) faster than clinical endpoints offering the potential to substantially speed up clinical trials i.e. the effectiveness of an anti-cancer drug can be compared against the rate of tumour growth, or progression free period, rather than mortality or how a patient feels
• Disease predisposition markers – biomarkers provide the ability to: screen for a disease, confirm it diagnostically, assess severity, predict drug treatment response pharmacogenomically, enable prescription of the correct pharmaceutical at the right time, and monitor the clinical course post-treatment
• Randox Pharma Services produces the broadest range of biomarker solutions of any diagnostic manufacturer, ensuring that your Biomarker discovery programmes are effective and targeted, all to aid the development of pharmaceuticals… faster, safer and more economically

For more information click here.